The size of the Liver Disease Treatment Market in the Middle-East & Africa is expected to reach USD 5.59 billion by 2027 from USD 3.19 billion in 2027, growing at a CAGR of 11.89% during the forecast period.
The increasing incidence of liver infections and diseases is majorly driving the liver disease treatment market in MEA. In addition, the growing population and the associated lifestyles such as unhealthy diets, excessive drinking of alcohol are fuelling the market growth. The ever-increasing geriatric population significantly influences the liver disease treatment market, as the senior population is prone to liver infections and various diseases. In addition, there has been a significant demand for this market in the recent past due to illnesses that have become common in middle east Africa.
Increasing investments by the government to create awareness among the people about the prevalence of cancer and availability of advanced treatments in the market through medical tourism and healthcare programs are projected to influence market growth positively.
One of the causes of fatty liver disease is overeating or obesity. Fatty liver disease is caused by the accumulation of too much fat in the liver. Obesity has been increasingly prevalent in recent years, with a significant increase in the number of persons affected. According to the World Health Organization, alcohol-related liver diseases and the obese population are on the rise, and these are the primary drivers of the liver disease treatment market.
The increase in population is also causing these liver disorders, owing to the increasing consumption of alcohol leading to liver cancer and liver cirrhosis. Therefore, key market players and governments are significantly investing in research and development activities which are expected to provide lucrative growth opportunities to the market growth.
However, strict government rules in the production of drugs, limited investments, complicated procedures in getting drug approval, and the high cost of drug manufacturing is majorly impeding the market growth. On the other hand, the side effects of the drugs and heavy competition from natural medicine further limit the market growth.
This research report on the MEA liver disease treatment market has been segmented and sub-segmented into the following categories:
By Treatment Modality:
By Disease Type:
Geographically, the MEA is anticipated to account for a moderate share in the global liver disease treatment market during the forecast period. The improving healthcare sector, high prevalence of liver diseases, and presence of key market players are propelling the market growth. In addition, emerging countries such South Africa, UAE, and Saudi Arabia are significantly expanding the MEA regional market.
South Africa accounted for the largest share of the market, and it is more likely to continue its growth during the forecast period. Liver disease has been the major problem in the country; several death cases are recorded due to the high prevalence. In addition, the growing awareness about liver diseases, increasing healthcare spending, and improving healthcare infrastructure.
On the other hand, other countries such as Saudi Arabia and UAE are projected to showcase a promising share during the forecast period. Increasing consumption of alcohol, growing population, and the associated lifestyles are boosting the market growth. In addition, the growing obese population is contributing to the market growth in these countries.
KEY MARKET PLAYERS:
Companies playing a leading role in the MEA liver disease treatment market profiled in the report are Gilead Science Inc. (U.S.), Pfizer Inc. (U.S.), Merck & Co. (U.S.), Johnson & Johnson (U.S.), Novartis (Switzerland), Roche (Switzerland), Sanofi-Aventis (France), Abbott Laboratories (U.S.), Bayer Schering AG (Germany) and AstraZeneca (United Kingdom).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 Treatment Modality
5.1.5 Immunosuppressive Agents
5.1.8 Y-o-Y Growth Analysis, By Product
5.1.9 Market Attractiveness Analysis, By Product
5.1.10 Market Share Analysis, By Product
5.2 Disease Type
5.2.3 Non-Alcoholic Fatty Liver Disease
5.2.4 Alcohol Induced
5.2.5 Liver Cancer
5.2.7 Y-o-Y Growth Analysis, By Type
5.2.8 Market Attractiveness Analysis, By Type
5.2.9 Market Share Analysis, By Type
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By Type
220.127.116.11 By Application
18.104.22.168 By Indication
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By Type
184.108.40.206 By Application
220.127.116.11 By Indication
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By Type
188.8.131.52 By Application
184.108.40.206 By Indication
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Gilead Science Inc
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Pfizer Inc.
8.3 Merck & Co.
8.4 Johnson & Johnson
8.8 Abbott Laboratories
8.9 Bayer Schering AG
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
Talk to our analyst and get customised report done according to your research needs
Check if you can avail any discount. Submit your details and our team will get back to you.
Request to avail a free sample report that reflects this market and its growth.